First-Line Treatment of Liver-Only Metastatic Colorectal Cancer Using Systemic or Intra-arterial Oxaliplatin with LV5FU2, Irinotecan, and Targeted Therapy
Led by Federation Francophone de Cancerologie Digestive · Updated on 2025-07-09
348
Participants Needed
49
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Colorectal cancer is a leading cause of cancer-related death, with many patients developing liver metastases that are often difficult to remove surgically. This trial focuses on first-line treatment for patients with metastatic colorectal cancer limited to the liver, aiming to evaluate the effectiveness of combining systemic chemotherapy, targeted therapies, and intra-arterial oxaliplatin chemotherapy. The study seeks to improve tumor response rates, progression-free survival, and overall survival in this patient group.
Participants will receive one of four treatment regimens involving combinations of oxaliplatin administered either intra-arterially or intravenously, along with folinic acid, 5-fluorouracil 5-FU, irinotecan, and targeted therapies such as panitumumab or bevacizumab depending on RAS mutation status. Treatment cycles occur every 15 days, with dosing tailored to each arm including variations in drug delivery methods and combinations. The trial includes both experimental and reference treatment arms to compare outcomes.
Throughout the study, participants will be monitored for progression-free survival up to 24 months after randomization. Assessments include measuring tumor response by RECIST criteria and evaluating liver metastases. Safety and tolerability will be tracked through laboratory tests and clinical evaluations, while participants eligibility and health status will be closely followed. The study duration extends up to 2028, with ongoing data collection to assess long-term outcomes and treatment effects.
CONDITIONS
Brief Title
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Research Team
S
Sofia JOURDAN
M
Marie MOREAU
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Recent abdominal fistula, gastrointestinal perforation, abscess, or active bleeding
Active gastroduodenal ulcer, wounds, or fractures
Recent major surgery or irradiation within 4 weeks
Transplant recipients, HIV positive, or other immune deficiency
Progressive severe organ failure within 6 months
Peripheral neuropathy greater than grade 1
Interstitial pneumonitis or pulmonary fibrosis
History of chronic diarrhea, inflammatory bowel disease, or unresolved bowel obstruction
Cancer history within 5 years except certain treated skin or cervical cancers
Participation in another experimental drug trial
Known allergies or hypersensitivity to study drugs
Deficiency in DPD enzyme
Abnormal QT/QTc intervals above specified limits
Low potassium, magnesium, or calcium levels
Lack of effective contraception or pregnancy
Persons deprived of liberty or under supervision
Inability to undergo medical monitoring due to geographic, social, or psychological reasons
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Repeated 15-day cycles while on treatment
Participants receive chemotherapy drugs including oxaliplatin (intravenous or intra-arterial), folinic acid, 5 fluorouracil (bolus and continuous), irinotecan (if assigned), and targeted therapy based on RAS mutation status.
1 visit every 15 days for each chemotherapy cycle
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Open-Label Study Evaluating BLU-924 Safety and Activity in Advanced Pancreatic, Lung, and Colorectal Cancers with KRAS Mutations
Evaluation of a Web-Based Decision Support Tool for Detecting Invasive Cancer in Large Colorectal Polyps During Colonoscopy
Study of a New Oral Synbiotic Formula to Lower Advanced Adenoma Recurrence and Related Bacterial Markers After Colorectal Neoplasia Removal
Phase III Study of UCB4594, a Monoclonal Antibody Targeting HLA-G, Alone and With Other Cancer Treatments in Adults With Advanced Solid Tumors
Phase 3 Study Comparing FOLFIRI With or Without Bevacizumab to Irinotecan With or Without Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer
Randomized Study Comparing Amivantamab Plus FOLFIRI Versus Cetuximab or Bevacizumab Plus FOLFIRI in Adults With KRASNRAS and BRAF Wild-type Recurrent or Metastatic Colorectal Cancer After Prior Chemotherapy
Randomized Study Comparing Amivantamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy for First-line Treatment of KRASNRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Study of DM002 Drug for Adults With Advanced Solid Tumors Using Increasing Doses to Find the Best Treatment Level
Phase 1 Study of JNJ-89402638 Alone and with Bevacizumab or Chemotherapy for Metastatic Colorectal and Gastric Cancers
Evaluating LY4257496 Radioligand Therapy in Adults With GRPR-Positive Advanced Solid Tumors Including Breast, Colorectal, and Prostate Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.